06/17/2025 5:05 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/13/2025 5:00 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/30/2025 7:31 AM | Innate Pharma (Subject) Innate Pharma SA (Subject) NOVO NORDISK A S (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
05/27/2025 5:03 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/23/2025 5:11 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/23/2025 5:17 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/19/2025 5:03 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/15/2025 5:00 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/13/2025 5:03 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/12/2025 5:03 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/06/2025 5:01 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
Get the Latest News and Ratings for IPHYF and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter.
|
04/30/2025 10:31 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/30/2025 8:01 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 20-F Registration statement / Annual report / Transition report | |
04/29/2025 5:48 PM | Innate Pharma (Subject) Innate Pharma SA (Subject) Sanofi (Filed by) Sanofi (Filed by)
| Form SCHEDULE 13G/A | |
04/29/2025 2:02 PM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/28/2025 5:00 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/24/2025 5:03 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/23/2025 7:28 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/16/2025 5:05 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/16/2025 5:07 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/03/2025 5:00 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
03/27/2025 6:01 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
03/26/2025 6:07 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
03/25/2025 6:23 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
03/20/2025 6:24 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/27/2025 5:01 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/18/2025 5:16 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/27/2025 6:57 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/21/2025 5:00 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/16/2025 7:16 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/10/2025 5:01 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/20/2024 6:03 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/09/2024 5:04 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/06/2024 5:00 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/03/2024 5:03 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/20/2024 5:02 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/19/2024 5:01 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/13/2024 5:00 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/08/2024 5:00 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/07/2024 5:00 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/29/2024 6:03 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
Is Elon's empire crumbling? (Ad) The Tesla Shock Nobody Sees Coming
While headlines scream "Tesla is doomed"...
Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs.
One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd. Click here to see the Tesla shock that could blindside everyone. |
10/15/2024 5:11 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/30/2024 5:15 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/23/2024 5:03 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/12/2024 5:15 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/12/2024 5:07 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/11/2024 3:00 PM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
09/09/2024 5:13 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/05/2024 5:10 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/04/2024 5:11 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/25/2024 5:06 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |